{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "mefenamic acid",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "After observing the response to initial therapy with mefenamic acid capsules, the dose and frequency should be adjusted to suit an individual patient's needs. 2.2 For the Management of Mild to Moderate Pain The recommended dosage in adults and pediatric patients 14 years of age and older is 500 mg given orally as an initial dose followed by 250 mg every 6 hours as needed.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "The safety and effectiveness of mefenamic acid capsules have been established for management of mild to moderate pain in pediatric patients 14 years of age and older. The safety and effectiveness of mefenamic acid capsules have been established for treatment of primary dysmenorrhea in pediatric patients.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "After observing the response to initial therapy with mefenamic acid capsules, the dose and frequency should be adjusted to suit an individual patient's needs. 2.2 For the Management of Mild to Moderate Pain The recommended dosage in adults and pediatric patients 14 years of age and older is 500 mg given orally as an initial dose followed by 250 mg every 6 hours as needed.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "( 8.3 ) 8.1 Pregnancy Risk Summary Use of NSAIDs, including mefenamic acid, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "Oligohydramnios/Neonatal Renal Impairment: If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effective dose and shortest duration possible.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "( 5.5 ) Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary Use of NSAIDs, including mefenamic acid, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "Because of these risks, limit dose and duration of mefenamic acid capsules use between about 20 and 30 weeks of gestation, and avoid mefenamic acid capsules use at about 30 weeks of gestation and later in pregnancy (see Clinical Considerations, Data) .",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "Premature Closure of Fetal Ductus Arteriosus Use of NSAIDs, including mefenamic acid capsules, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Infertility Females Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including mefenamic acid may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      },
      {
        "text": "Consider withdrawal of NSAIDs, including mefenamic acid, in women who have difficulties conceiving or who are undergoing investigation of infertility.",
        "source": "US FDA label for mefenamic acid (Mefenamic acid), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/mefenamic-acid.json",
        "verbatim": true
      }
    ]
  }
}